NASDAQ:XNCR Xencor (XNCR) Stock Price, News & Analysis $8.13 +0.08 (+0.99%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.13 0.00 (0.00%) As of 08/29/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Xencor Stock (NASDAQ:XNCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xencor alerts:Sign Up Key Stats Today's Range$7.83▼$8.1350-Day Range$7.00▼$9.5752-Week Range$6.92▼$27.24Volume769,384 shsAverage Volume749,722 shsMarket Capitalization$579.83 millionP/E RatioN/ADividend YieldN/APrice Target$23.71Consensus RatingModerate Buy Company Overview Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. Read More Xencor Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreXNCR MarketRank™: Xencor scored higher than 73% of companies evaluated by MarketBeat, and ranked 276th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingXencor has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXencor has only been the subject of 3 research reports in the past 90 days.Read more about Xencor's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Xencor are expected to grow in the coming year, from ($3.68) to ($3.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXencor has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Xencor's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.62% of the float of Xencor has been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Xencor has recently increased by 5.23%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-2.24 Percentage of Shares Shorted13.62% of the float of Xencor has been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Xencor has recently increased by 5.23%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment1.02 News SentimentXencor has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Xencor this week, compared to 4 articles on an average week.Search Interest2 people have searched for XNCR on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $103,209.00 in company stock.Percentage Held by InsidersOnly 4.76% of the stock of Xencor is held by insiders.Read more about Xencor's insider trading history. Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XNCR Stock News HeadlinesXencor to Participate at Upcoming Investor ConferencesAugust 27, 2025 | businesswire.comXencor, Inc. (NASDAQ:XNCR) Receives $23.71 Consensus Target Price from BrokeragesAugust 25, 2025 | americanbankingnews.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. August 31 at 2:00 AM | Crypto 101 Media (Ad)Royal Bank Of Canada Lowers Xencor (NASDAQ:XNCR) Price Target to $15.00August 23, 2025 | americanbankingnews.comXencor price target lowered to $15 from $32 at RBC CapitalAugust 21, 2025 | msn.comXencor (XNCR) Receives a Buy from Leerink PartnersAugust 9, 2025 | theglobeandmail.comXencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesAugust 9, 2025 | finance.yahoo.comXencor (XNCR) Q2 Revenue Jumps 82%August 9, 2025 | theglobeandmail.comSee More Headlines XNCR Stock Analysis - Frequently Asked Questions How have XNCR shares performed this year? Xencor's stock was trading at $22.98 at the beginning of 2025. Since then, XNCR shares have decreased by 64.6% and is now trading at $8.13. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) released its earnings results on Wednesday, August, 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.37. The firm's quarterly revenue was up 82.4% on a year-over-year basis. Who are Xencor's major shareholders? Xencor's top institutional investors include Primecap Management Co. CA (14.76%), Geode Capital Management LLC (2.39%), Bank of America Corp DE (1.32%) and Nantahala Capital Management LLC (1.15%). Insiders that own company stock include Bassil I Dahiyat, John R Desjarlais, John J Kuch, Allen Yang, Nancy Valente, Celia Eckert, Alan Bruce Montgomery, Kurt A Gustafson, Ellen Feigal and Richard J Ranieri. View institutional ownership trends. How do I buy shares of Xencor? Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xencor investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/06/2025Today8/31/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XNCR CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees280Year FoundedN/APrice Target and Rating Average Price Target for Xencor$23.71 High Price Target$34.00 Low Price Target$6.00 Potential Upside/Downside+191.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$232.62 million Net Margins-121.52% Pretax Margin-122.54% Return on Equity-25.75% Return on Assets-18.19% Debt Debt-to-Equity RatioN/A Current Ratio5.34 Quick Ratio5.34 Sales & Book Value Annual Sales$110.49 million Price / Sales5.25 Cash FlowN/A Price / Cash FlowN/A Book Value$8.70 per share Price / Book0.93Miscellaneous Outstanding Shares71,320,000Free Float67,928,000Market Cap$579.83 million OptionableOptionable Beta0.89 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:XNCR) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.